First head-to-head comparison of CDK4/6 inhibitors in cell line and animal models of breast cancer reveals important differences, including one drug that exhibits unique, potentially advantageous therapeutic activity.
Comparison of three similar frontline breast cancer drugs reveals important differences
First head-to-head comparison of CDK4/6 inhibitors in cell line and animal models of breast cancer reveals important differences, including one drug that exhibits unique, potentially advantageous therapeutic activity.